220746-98-5

Basic information

• Product Name: ethyl 2-ethoxy-3-[4-(2-bromoethoxy)-phenyl]propanoate
• Synonyms: ethyl 2-ethoxy-3-[4-(2-bromoethoxy)-phenyl]propanoate
• CAS NO: 220746-98-5
• Molecular Weight: 345.233
• Mol File: 220746-98-5.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: ethyl 2-ethoxy-3-[4-(2-bromoethoxy)-phenyl]propanoate(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl 2-ethoxy-3-[4-(2-bromoethoxy)-phenyl]propanoate(220746-98-5)
• EPA Substance Registry System: ethyl 2-ethoxy-3-[4-(2-bromoethoxy)-phenyl]propanoate(220746-98-5)

Safety Data

• Hazardous Substances Data: 220746-98-5(Hazardous Substances Data)

Upstream product

• 540-51-2 2-bromoethanol 
• 197299-16-4 ethyl 2-ethoxy-3-(4-hydroxy-phenyl)-propionate 
• 123-08-0 4-hydroxy-benzaldehyde 
• 4397-53-9 p-benzyloxybenzaldehyde 
• 52191-15-8 4-(2-bromoethyloxy)benzaldehyde 
• 106-93-4 ethylene dibromide 

Downstream Products

• 544478-57-1 2-ethoxy-3-{4-[2-(6-oxo-5,6-dihydro-4-oxa-1-thia-7-aza-inden-7-yl)-ethoxy]-phenyl}-propionic acid ethyl ester 
• 952481-02-6 C₂₉H₄₄N₂O₄ 
• 911381-01-6 ethyl 2-ethoxy-3-(4-{2-[2-(trifluoromethyl)-1H-benzimidazol-1-yl]ethoxy}phenyl)propanoate 
• 911381-15-2 [2S,N(1S)]-3-{4-[2-(2-trifluoromethyl-benzoimidazol-1-yl)-ethoxy]-phenyl}-2-ethoxy-N-(2-hydroxy-1-phenylethyl)propionamide 
• 911381-13-0 [2R,N(1S)]-3-{4-[2-(2-trifluoromethyl-benzoimidazol-1-yl)-ethoxy]-phenyl}-2-ethoxy-N-(2-hydroxy-1-phenylethyl)propionamide 
• 408512-86-7 (+/-) Ethyl 2-ethoxy-3-[4-[2-[2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl]ethoxy]phenyl]propanoate 
• 220746-95-2 ethyl 3-(4-(2-aminoethoxy)phenyl)-2-ethoxypropionate 
• 264881-88-1 ethyl 3-(4-(N-methyl-N-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)aminoethoxy)phenyl)-2-ethoxypropionate 

Relevant articles and documents

Anti-diabetic activity of fused PPARγ-SIRT1 ligands with limited body-weight gain by mimicking calorie restriction and decreasing SGK1 expression

A series of benzothiazol-2-one containing α-ethoxyphenylpropionic acid derivatives incorporating resveratrol or butein scaffolds were designed as fused full PPARγ agonist ligands and SIRT1-activating compounds for the treatment of type 2 diabetes (T2D) an

SUBSTITUTED CARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT OF DIABETES AND LIPID DISORDERS, THEIR PREPARATION AND USE

The present invention is concerned with racemic or enantiomerically enriched substituted carboxylic acids and derivatives thereof represented by Formula 1 ; or pharmaceutically acceptable salts thereof. The present invention also includes pharmaceutical c

Tricyclic compounds and their use in medicine: process for their preparation and pharmaceutical compositions containing them

A compound of formula (1) it derivatives, its analogs, its tautomeric forms, its stereoisomers, its polymorphs, its pharmaceutically acceptable salts, or its pharmaceutically acceptable solvates, processes for its preparation and methods of use thereof.